BOSTON–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced that company leadership will participate in two upcoming investor conferences in March:
- TD Cowen 44th Annual Health Care Conference, Monday, March 4 through Wednesday, March 6, 2024 in Boston, MA
- Leerink Partners Global Biopharma Conference 2024, Monday, March 11 through Wednesday, March 13, 2024 in Miami, FL
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The Company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara’s lead product candidate, BCA101, is a first-in-class EGFR/TGF-β-trap bifunctional antibody in clinical development for multiple tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.
Contacts
Investors
Hannah Deresiewicz
Stern Investor Relations, Inc.
Hannah.Deresiewicz@sternir.com
Media
Dan Budwick
1AB
dan@1abmedia.com